The impact of surgical resection in early onset colorectal cancer patients with liver limited disease.
Abstract
e15569 Background: Recent studies have shown an increased incidence of early-onset CRC (EO-CRC), particularly in advanced stages and with metastatic disease. Our study aimed to evaluate the role of metastasectomies related to the clinical and molecular characteristics of EO-CRC patients with liver metastases compared to late-onset CRC (LO-CRC) patients. Methods: We retrospectively collected data from 1123 stage IV colorectal cancers, including 782 with liver metastases, from 5 different Italian institutions. The main objective of the study was to compare the overall survival of liver metastatic EO-CRC and LO-CRC patients who underwent metastasectomy versus those who were not resected. Results: Liver resected EO-CRCs patients showed a statistically significant lower mOS than liver resected LO-CRCs (44.0 vs 64.0 months, p < 0.0001 ). mPFS was also statistically significant lower in EO-CRCs (13.0 vs 17.0, p < 0.0001 ). Same outcomes were found in RAS mut subgroup (37.0 vs 52.0 months, p < 0.0001) and in RAS/BRAF wild-type subgroup (50.0 vs 81.0 months, p < 0.0001). EO-CRC patients showed a higher prevalence of TP53 alterations (56.2%) and a lower of APC mutation (29.9%). EO-CRCs presented a higher frequency of ARID1A (4.4%) and CTNNB1 (3.0%) alterations. Conclusions: The results indicate a worse overall prognosis for EO-CRC patients undergoing metastasectomy compared to late-onset patients. This outcome appears to occur independently of the molecular status. These observations could have a considerable impact on clinical practice and research.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (20)
Andrea Pretta
Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy
Francesca Bergamo
Federica Marmorino
Federica Bertuzzi
Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Pina Ziranu
Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy
Krisida Cerma
Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
Paolo Ciracì
Federica Manoni
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Clelia Donisi
Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy
Maria Caterina De Grandis
Medical Oncology 1, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy
Ada Taravella
Silvia Marchesi
Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Valeria Pusceddu
Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy
Giulia Maddalena
Medical Oncology 1, Veneto Institute of Oncology IOV-IRCSS, Padua, Italy
Roberta Fazio
Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, NA, Italy
Riccardo Giampieri
Filippo Pietrantonio
Chiara Cremolini
Sara Lonardi
Mario Scartozzi
Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy